Recombivax Hb

Recombivax Hb Manufacturers

• Remedyrepack Inc.
  

  ×

  Recombivax Hb | Remedyrepack Inc.

  

  ---

  0.5-mL suspension for intramuscular injection at the following schedule: 0, 2 months, 6 months. (2.1)

   

  GARDASIL should be administered intramuscularly as a 0.5-mL dose at the following schedule: 0, 2 months, 6 months. [See Clinical Studies (14.8).]

   

  For intramuscular use only.

  Shake well before use. Thorough agitation immediately before administration is necessary to maintain suspension of the vaccine. GARDASIL should not be diluted or mixed with other vaccines. After thorough agitation, GARDASIL is a white, cloudy liquid. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. Do not use the product if particulates are present or if it appears discolored.

  GARDASIL should be administered intramuscularly in the deltoid region of the upper arm or in the higher anterolateral area of the thigh.

  Syncope has been reported following vaccination with GARDASIL and may result in falling with injury; observation for 15 minutes after administration is recommended. [See Warnings and Precautions (5.1).]

  Single-Dose Vial Use

  Withdraw the 0.5-mL dose of vaccine from the single-dose vial using a sterile needle and syringe and use promptly.

  Prefilled Syringe Use

  This package does not contain a needle. Shake well before use. Attach the needle by twisting in a clockwise direction until the needle fits securely on the syringe. Administer the entire dose as per standard protocol.

   

  Close
  No Recall

  More Info
• Merck Sharp & Dohme Corp.
  

  ×

  Recombivax Hb | Merck Sharp & Dohme Corp.

  

  ---

  For intramuscular administration. See Section 2.2 for subcutaneous administration in persons with hemophilia.

  2.1 Dosage and Schedule

  RECOMBIVAX HB:

  Persons from birth through 19 years of age: A series of 3 doses (0.5 mL each) given on a 0-, 1-, and 6-month schedule.

  Adolescents 11 through 15 years of age: A series of 3 doses (0.5 mL each) given on a 0-, 1-, and 6-month schedule or a series of 2 doses (1.0 mL each) on a 0- and 4- to 6-month schedule.

  Persons 20 years of age and older: A series of 3 doses (1.0 mL each) given on a 0-, 1-, and 6-month schedule.

  RECOMBIVAX HB Dialysis Formulation:

  Adults on predialysis and dialysis: A series of 3 doses (1.0 mL each) given on a 0-, 1-, and 6-month schedule.

  Table 1 summarizes the dose and formulation of RECOMBIVAX HB for specific populations, regardless of the risk of infection with hepatitis B virus.

  Table 1: RECOMBIVAX HB Recommended Dose and Administration Schedules Group Dose/Regimen * For specific recommendations for infants see ACIP recommendations.{1} † Adolescents (11 through 15 years of age) may receive either regimen: 3 × 5 mcg (Pediatric Formulation) or 2 × 10 mcg (Adult Formulation). ‡ If the suggested dose (10 mcg) is not available, the appropriate dosage can be achieved with two 5 mcg doses. However, the Dialysis Formulation may be used only for adult predialysis/dialysis patients. § See also recommendations for revaccination of predialysis and dialysis patients in [Dosage and Administration (2.4)]. Infants*, Children and Adolescents
  0-19 years of age
  (Pediatric/Adolescent Formulation) 5 mcg (0.5 mL)
  3 doses at 0, 1, and 6 months Adolescents†
  11 through 15 years of age
  (Adult formulation) 10 mcg‡ (1.0 mL)
  2 doses at 0 and 4-6 months Adults
  ≥20 years of age
  (Adult formulation) 10 mcg‡ (1.0 mL)
  3 doses at 0, 1, and 6 months Predialysis and Dialysis Patients§
  (Dialysis formulation) 40 mcg (1.0 mL)
  3 doses at 0, 1, and 6 months 2.2 Preparation and Administration

  Shake the single-dose vial or single-dose prefilled syringe well to obtain a slightly opaque, white suspension before withdrawal and use. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Discard if the suspension does not appear homogeneous or if extraneous particulate matter remains or if discoloration is observed.

  For single-dose vials, withdraw and administer entire dose of RECOMBIVAX HB intramuscularly using a sterile needle and syringe.

  For single-dose prefilled syringes, securely attach a needle by twisting in a clockwise direction and administer dose of RECOMBIVAX HB intramuscularly.

  The deltoid muscle is the preferred site for intramuscular injection for adults, adolescents and children 1 year of age and older whose deltoid is large enough for intramuscular injection. The anterolateral aspect of the thigh is the preferred site for intramuscular injection for infants younger than 1 year of age. RECOMBIVAX HB should not be administered in the gluteal region, as injections given in the buttocks have resulted in lower seroconversion rates than expected.{2}

  RECOMBIVAX HB may be administered subcutaneously to persons at risk for hemorrhage following intramuscular injections (e.g., hemophiliacs). However, hepatitis B vaccines are known to result in lower antibody response when administered subcutaneously.{3} Additionally, when other aluminum-adsorbed vaccines have been administered subcutaneously, an increased incidence of local reactions including subcutaneous nodules has been observed. Therefore, consider subcutaneous administration only in persons who are at risk of hemorrhage following intramuscular injections.

  Do not administer intravenously or intradermally

  2.3 Known or Presumed Exposure to Hepatitis B Virus

  Known or Presumed Exposure to HBsAg

  Refer to recommendations of the Advisory Committee on Immunization Practices (ACIP) and to the package insert for hepatitis B immune globulin (HBIG) for management of persons with known or presumed exposure to the hepatitis B virus (e.g., neonates born of infected mothers or persons who experienced percutaneous or permucosal exposure to the virus). When recommended, administer RECOMBIVAX HB and HBIG intramuscularly at separate sites (e.g., opposite anterolateral thighs for exposed neonates) as soon as possible after exposure. Administer additional doses of RECOMBIVAX HB (to complete a vaccination series) in accordance with ACIP recommendations.

  2.4 Booster Vaccinations

  The duration of the protective effect of RECOMBIVAX HB in healthy vaccinees is unknown at present and the need for booster doses is not yet defined. The ACIP provides recommendations for use of a booster dose or revaccination series in previously vaccinated individuals with known or presumed exposure to Hepatitis B Virus.

  Consider a booster dose or revaccination with RECOMBIVAX HB Dialysis Formulation (blue color code) in predialysis/dialysis patients if the anti-HBs level is less than 10 mIU/mL at 1 to 2 months after the third dose. Assess the need for a booster dose annually by antibody testing, and give a booster dose when the anti-HBs level declines to less than 10 mIU/mL.{3}

  Close
  No Recall

  More Info